Table 3.
Avoidance of serious adverse drug reactions
| No. | Case | Pharmaceutical intervention |
|---|---|---|
| 1 | Renal function worsening due to a combination of fibrates and statins | Discontinue fibrates |
| 2 | Lithium intoxication and acute renal failure in patients orally administered lithium carbonate | Measure blood lithium concentration and discontinue lithium carbonate |
| 3 | Liver dysfunction because of phenytoin | Change to other anti-epileptic drugs |
| 4 | Hypoglycemia with oral diabetes drugs | Reduce dose of oral diabetes drugs |
| 5 | Pancytopenia after an increase in carbamazepine dosage | Discontinue carbamazepine |
| 6 | Bevacizumab administered to a patient with planned tooth extraction | Change to chemotherapy without bevacizumab |
| 7 | Start of chemotherapy for grade 4 neutropenic patients | Postpone chemotherapy |
| 8 | No blood test after chemotherapy (grade 4 neutropenia) | Recommend blood test |
| 9 | Onset of grade 2 peripheral neuropathy after chemotherapy | Begin adjuvant analgesics |
| 10 | Anaphylaxis by premedication at start of chemotherapy | Change premedication |
| 11 | Start of chemotherapy for patients untreated for HBV-DNA-positive conversion | Postpone chemotherapy and begin oral administration of entecavir |
| 12 | Start of chemotherapy for patients untreated for HBV-DNA detection | Begin oral administration of entecavir |
HBV Hepatitis B virus